Cite
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, random ised controlled trial.
MLA
Yung-Jue Bang, et al. “Adjuvant Capecitabine and Oxaliplatin for Gastric Cancer after D2 Gastrectomy (CLASSIC): A Phase 3 Open-Label, Random Ised Controlled Trial.” Lancet, vol. 379, no. 9813, Jan. 2012, pp. 315–21. EBSCOhost, https://doi.org/10.1016/S0140-6736(11)61873-4.
APA
Yung-Jue Bang, Young-Woo Kim, Han-Kwang Yang, Hyun Cheol Chung, Young-Kyu Park, Kyung Hee Lee, Keun-Wook Lee, Yong Ho Kim, Sang-Ik Noh, Joe Yong Cho, Young Joe Mok, Yeul Hong Kim, Jiafu Ji, Ta-Sen Yeh, Button, P., Sirzén, F., & Sung Hoon Noh. (2012). Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, random ised controlled trial. Lancet, 379(9813), 315–321. https://doi.org/10.1016/S0140-6736(11)61873-4
Chicago
Yung-Jue Bang, Young-Woo Kim, Han-Kwang Yang, Hyun Cheol Chung, Young-Kyu Park, Kyung Hee Lee, Keun-Wook Lee, et al. 2012. “Adjuvant Capecitabine and Oxaliplatin for Gastric Cancer after D2 Gastrectomy (CLASSIC): A Phase 3 Open-Label, Random Ised Controlled Trial.” Lancet 379 (9813): 315–21. doi:10.1016/S0140-6736(11)61873-4.